Skip to main content

hyperCORE International Announces Two Appointments to Executive Leadership





Gwen Welty joins the clinical research super network as Executive Director and Karri Venn as Executive Consultant

COLUMBUS, GA, February 11, 2024 /24-7PressRelease/ -- hyperCORE International, a collaborative network of clinical trial sites across North America, welcomes the addition of two highly regarded industry executives to its leadership team, effective immediately.

Gwen Welty joined as the Executive Director to lead the operations of hyperCORE. Ms. Welty brings extensive experience in both the CRO and Site industries making her a very strong addition to hyperCORE as it continues to evolve relationships with Sponsors and CROs. She can be reached at gwelty@hypercoreinternational.com and welcomes engagement.

Karri Venn joined as an Executive Consultant to drive the strategic direction of hyperCORE in an industry that is rapidly transitioning from Full Service Outsourcing (FSO) to Functional Service Providers (FSP). With decades of experience in leading successful site operations, Ms. Venn's knowledge of the site landscape will be instrumental in hyperCORE's mission to accelerate research through collaboration with industry CRO and Sponsor partners. She can be reached at kvenn@hypercoreinternational.com.

hyperCORE looks forward to engaging industry partners at SCOPE 2024 in Orlando where the executive team and several Alliance Partners will be in attendance.

If you are interested in connecting, please email Gwen Welty or Jamie Metcalf (jmetcalf@hypercoreinternational.com).

Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 100 active research sites on two continents and five countries. Each of its alliance partners have decades of clinical research experience and have collectively completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 randomized patients. While operating independently, each partner integrates common functions to optimize business and clinical operations through harmonization and sharing of best practices.

hyperCORE International is dedicated to upholding the highest standards of research excellence, with subject safety, data integrity, rapid study startup, competitive enrollment, and exceptional subject retention as top priorities. Its members have earned numerous awards for performance, quality, and innovation.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.